AstraZeneca's $100 million R&D strategy for China includes a significant focus on outsourcing in Asia. Research chief Steve Yang says AstraZeneca ($AZN) doesn't want to simply replicate the work it does in the U.S. and Europe. By taking what they know about biomarkers and patient selection, its investigators want to craft a new approach that targets specific disease challenges--such as high rates of gastric and liver cancers--and builds on its tech skills. And to maximize efficiency, the company wants to pursue R&D outsourcing as it forges new research ties with academic groups as well as biotech companies. Story